Pfizer Inc.

NYSE:PFE  
54.94
-0.60 (-1.08%)
4:58:11 PM EDT: $54.92 -0.02 (-0.04%)
Products

Pfizer Plans To File NDA With FDA For Full Regulatory Approval In 2022 For Paxlovid

Published: 12/22/2021 17:35 GMT
Pfizer Inc. (PFE) - Pfizer - Paxlovid is Authorized for Emergency Use in High-risk Adults and High-risk Pediatric Patients 12 Yrs and Older Weighing at Least 40 Kg.
Pfizer - Raises Production Projections for Paxlovid From 80 Million to 120 Million Courses of Treatment in 2022.
Pfizer Receives U.S. FDA Emergency Use Authorization for Novel Covid-19 Oral Antiviral Treatment.
Pfizer - Ready to Start Delivery of Paxlovid in U.S. Immediately.
Pfizer - Plans to File a New Drug Application With the FDA for Full Regulatory Approval in 2022 for Paxlovid.
Further Company Coverage:pfen ((reuters.
Briefs@thomsonreuters.
Com;)).